SOURCE: CLX Investment Company, Inc.

August 23, 2007 09:34 ET

CLX Investment Company Announces Launch of Investor Newsletter With September 2007 Edition

Shareholders Are Encouraged to Subscribe to Email Alerts to Receive Newsletter and Press Release Notifications

MURRIETA, CA--(Marketwire - August 23, 2007) - CLX Investment Company, Inc. (OTCBB: CLXN) today announced that in order to provide more comprehensive information on the company's expected acquisition of Zonda, Incorporated, CLX is planning to re-launch its monthly investor newsletter with a September 2007 edition.

The first edition of the re-launched investor newsletter is expected to be released on Tuesday, September 3rd. A press release will accompany the posting of the newsletter on the CLX website,, and a notice will be distributed through the company's website-based E-mail Alert System. To sign up to receive the newsletter notification, shareholders and others interested in the company should visit and fill in the appropriate fields.

A PDF version of each newsletter, complete with photographs and other graphics suitable for printing, will be made available at

A major focus of the first newsletter issues will be the expected acquisition of Zonda, which develops and manufactures unique diagnostic tests for both the medical and non-medical markets. CLX and Zonda have executed an initial agreement in the form of a letter of intent under which CLX would acquire the remaining issued and outstanding shares of Zonda. Once the remaining due diligence is complete, the companies expect to reach a definitive agreement regarding the acquisition.

"We expect to move forward with our acquisition of Zonda relatively quickly, so the monthly investor newsletter will play an important role in augmenting the story of CLX and Zonda," stated Steven R. Peacock, consultant chief executive officer of CLX Investment Company. "We have found the monthly newsletters to be an extremely important communications tool, and we strongly encourage our shareholders and those interested in the Zonda acquisition to subscribe to CLX's email alerts.

"One article that we expect to feature in our very first newsletter edition is a comprehensive profile of Zonda CEO Vera Leonard, including an interview, in which Ms. Leonard can provide her insights into the opportunity that Zonda presents for CLX shareholders. We feel that Ms. Leonard is a tremendous asset to Zonda, and her extensive experience in the medical manufacturing and distribution field will be extremely useful as Zonda targets U.S. distribution for its Chlamydia product," Mr. Peacock added.

About Zonda, Incorporated

Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point-of-care, and the over-the-counter (OTC) markets.

Zonda's strong intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point-of-care diagnostic tests. The company's first medical test, for Chlamydia, is expected to launch in the U.S. at the end of the first quarter 2008. Zonda believes it will compete successfully with all current technologies, including the "gold standard" nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.

About CLX Investment Company

CLX Investment Company ( holds a 41% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact